Dossier
obesity drug discount program
Coverage of obesity drug discount program in the Nexus archive.
- STAT+: Roche ends Huntington’s gene-silencing programs
Roche has discontinued two Huntington’s gene-silencing drugs due to disappointing data. ARPA-H announced a $160 million initiative to accelerate gene-editing therapies for rare diseases. Drugmakers are promoting Medicare’s new obesity drug discount program.